Healthcare provider profile · identity verified

Fadi Sabbagh, M.D.

Pulmonary Disease · EAU CLAIRE, WI · NPI 1275597858

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Montelukast Sodium	Montelukast Sodium	351	87
Albuterol Sulfate Hfa	Albuterol Sulfate	255	60
Atorvastatin Calcium	Atorvastatin Calcium	214	59
Gabapentin	Gabapentin	195	48
Prednisone	Prednisone	179	50
Furosemide	Furosemide	165	52
Metoprolol Succinate	Metoprolol Succinate	161	46
Omeprazole	Omeprazole	154	45
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	132	26
Losartan Potassium	Losartan Potassium	127	38
Spironolactone	Spironolactone	127	35
Azithromycin	Azithromycin	126	53
Amlodipine Besylate	Amlodipine Besylate	119	32
Tramadol Hcl	Tramadol Hcl	119	33
Lisinopril	Lisinopril	115	33
Eliquis	Apixaban	111	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	108	40
Zolpidem Tartrate	Zolpidem Tartrate	102	16
Potassium Chloride	Potassium Chloride	100	22
Breo Ellipta	Fluticasone/Vilanterol	98	15
Alprazolam	Alprazolam	95	24
Levothyroxine Sodium	Levothyroxine Sodium	94	29
Duloxetine Hcl	Duloxetine Hcl	88	19
Fluticasone Propionate	Fluticasone Propionate	86	33
Buspirone Hcl	Buspirone Hcl	84	18
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	76	19
Metoprolol Tartrate	Metoprolol Tartrate	72	26
Pantoprazole Sodium	Pantoprazole Sodium	65	23
Metformin Hcl	Metformin Hcl	63	21
Symbicort	Budesonide/Formoterol Fumarate	63	13
Warfarin Sodium	Warfarin Sodium	59	14
Rosuvastatin Calcium	Rosuvastatin Calcium	55	13
Incruse Ellipta	Umeclidinium Bromide	48	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	48	13
Nucala	Mepolizumab	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	44	14
Allopurinol	Allopurinol	43	11
Clonazepam	Clonazepam	40	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	suppressed
Clopidogrel	Clopidogrel Bisulfate	39	suppressed
Trazodone Hcl	Trazodone Hcl	39	suppressed
Paroxetine Hcl	Paroxetine Hcl	38	suppressed
Celecoxib	Celecoxib	35	12
Citalopram Hbr	Citalopram Hydrobromide	35	suppressed
Ezetimibe	Ezetimibe	35	suppressed
Mirtazapine	Mirtazapine	35	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	35	suppressed
Pregabalin	Pregabalin	34	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	32	suppressed
Cefuroxime	Cefuroxime Axetil	31	25
Spiriva Handihaler	Tiotropium Bromide	31	suppressed
Spiriva Respimat	Tiotropium Bromide	31	suppressed
Oxycodone Hcl	Oxycodone Hcl	29	12
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	28	suppressed
Bumetanide	Bumetanide	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	27	suppressed
Carvedilol	Carvedilol	25	suppressed
Lorazepam	Lorazepam	25	suppressed
Dulera	Mometasone/Formoterol	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Simvastatin	Simvastatin	24	suppressed
Sertraline Hcl	Sertraline Hcl	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	13
Morphine Sulfate Er	Morphine Sulfate	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Temazepam	Temazepam	21	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Atenolol	Atenolol	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	suppressed
Pirfenidone	Pirfenidone	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Torsemide	Torsemide	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Baclofen	Baclofen	14	suppressed
Nystatin	Nystatin	14	suppressed
Roflumilast	Roflumilast	14	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Ozempic	Semaglutide	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Armodafinil	Armodafinil	12	suppressed
Atrovent Hfa	Ipratropium Bromide	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Famotidine	Famotidine	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Lurasidone Hcl	Lurasidone Hcl	11	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error